PFO
ONCT

Pathstone Family Office’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Pathstone Family Office’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-121
Closed -$12K – 1407
2020
Q4 		$12K Buy
+121
New +$7.66K ﹤0.01% 853

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return

Pathstone Family Office's ONCT Position: Q1 2021 in Review

Pathstone Family Office sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2021, closing a stake of 121 shares — an estimated $12K sold.

Pathstone Family Office first reported a position in ONCT in Q4 2020 and held it in 1 quarter. The position peaked at $12K in Q4 2020. 64 funds tracked by Wall St. Rank hold ONCT as of Q1 2021.

  • Pathstone Family Office reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Pathstone Family Office sold 121 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $12K.
  • Pathstone Family Office first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Pathstone Family Office's Oncternal Therapeutics, Inc. Common Stock position peaked at $12K in Q4 2020.
  • 64 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Pathstone Family Office's 13F filing for Q1 2021, filed 14 May 2021.